Abstract
Objective
To examine the effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Aprepitant is a neurokinin-1 (NK1)-receptor antagonist developed as an antiemetic for chemotherapy-induced nausea and vomiting.
Methods
This was a double-blind, placebo-controlled, randomized, two-period, parallel-group study. During period 1, warfarin was individually titrated to a stable prothrombin time (expressed as international normalized ratio, INR) from 1.3 to 1.8. Subsequently, the daily warfarin dose remained fixed for 10–12 days. During period 2, the warfarin dose was continued for 8 days, and on days 1–3 administered concomitantly with aprepitant (125 mg on day 1, and 80 mg on days 2 and 3) or placebo. At baseline (day −1 of period 2) and on day 3, warfarin pharmacokinetics was investigated. INR was monitored daily. During period 2, warfarin trough concentrations were determined daily.
Results
The study was completed by 22 healthy volunteers (20 men, 2 women). On day 3, steady-state pharmacokinetics of warfarin enantiomers after aprepitant did not change, as assessed by warfarin AUC0-24h and Cmax. However, compared with placebo, trough S(−) warfarin concentrations decreased on days 5–8 (maximum decrease 34% on day 8, P<0.01). The INR decreased after aprepitant with a mean maximum decrease on day 8 of 11% versus placebo (P=0.011).
Conclusion
These data are consistent with a significant induction of CYP2C9 metabolism of S(−) warfarin by aprepitant. Subsequently, in patients on chronic warfarin therapy, the clotting status should be monitored closely during the 2-week period, particularly at 7–10 days, following initiation of the 3-day regimen of aprepitant with each chemotherapy cycle.
Similar content being viewed by others
References
Mc Crea JB, Majumdar AK, Goldberg MR, Iwamoto M, Gargano C, Panebianco DL, Hesney M, Lines CR, Petty K, Deutsch PJ, Murphy MG, Gottesdiener KM, Goldwater R, Blum RA (2003) Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 74(1):17–24
Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan K (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomised, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. J Clin Oncol 21:22
Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C, Martinez-Cedillo J, Erazo A, Wittreich J, Eriksson LO, Carides AD, Gertz BJ (2001) Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-0869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 19:1759–1767
Emend product information. West point, PA: Merck& Co., Inc., 2003
Huskey S, Dean B, Doss G, Wang Z, Hop C, Anari R, Finke P, Robichaud A, Zhang M, Wang B, Strauss J, Cunningham P, Feeney W, Franklin R, Baillie T, Chiu SH (2004) The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs. Drug Metab Dispos 32:246–258
Hirsh J (1991) Oral anticoagulant drugs. N Engl J Med 324:1865–1875
Chan E, McLachlan A, O’Reilly R, Rowland M (1994) Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic–pharmacodynamic model. Clin Pharmacol Ther 56:286–294
Harder S, Thurmann P (1996) Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 30:416–444
Internal bioanalytical report. Merck Research Laboratories, Westpoint, PA, 2002.
Steinijans VW, Hartmann H, Huber R, Radtke HW (1991) Lack of pharmacokinetic interaction as an equivalence problem. J Clin Pharmacol Ther Toxicol 29:323–328
Grind M, Murphy M, Warrington S, Aberg J (1993) Method for studying drug-warfarin interactions. Clin Pharmacol Ther 54(4):381–387
Majumdar A, McCrea J, Panebianco D, Hesney M, Dru J, Constanzer M, Goldberg M, Murphy G, Gottesdiener K, Lines C, Petty K, Blum R (2003) Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther 74:150–156
Shadle C, Lee Y, Majumdar A, Petty K, Gargano C, Bradstreet T, Evans J, Blum R (2004) Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 44(3):215–223
Acknowledgements
This study was supported by a grant from Merck and Co. Inc., NJ, USA.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Depré, M., Van Hecken, A., Oeyen, M. et al. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol 61, 341–346 (2005). https://doi.org/10.1007/s00228-005-0907-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-005-0907-8